List view / Grid view
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.
Researchers have developed a nanobody that can penetrate the tough exterior of brain cells and untangle misshapen proteins that lead to Parkinson’s disease.
Scientists are developing an effective stem cell-based therapy to regenerate photoreceptors cells and restore sight in people with blindness.
In this exclusive interview for World Hepatitis Day with Drug Target Review, Professor Ziv Ben Ari from the Sheba Medical Center discusses recent progress towards hepatitis treatment.
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
Researchers have discovered a new pathway to the regeneration of insulin in pancreatic stem cells, findings that could move towards new therapies for type 1 and type 2 diabetes.
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
The scientists found that the neutralising monoclonal antibody protected against SARS-CoV-2 infections in animal experiments.
Scientists at the University of Pittsburgh have been using computational modelling to understand the body’s immune responses to avian flu.
A new computer-based approach could help clinicians select the best combinations of broadly neutralising antibodies to treat HIV based on the virus’ genetics, while minimising the risk of the virus escaping treatment.
A new study has found that the latest Omicron subvariants are even better at avoiding vaccines and most antibody treatments than previous variants.
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.
Researchers have created a new implant device has the potential to provide an alternative to opioids and other highly addictive drugs.
For the first time, researchers have tested a molecule that combines three distinct technologies against glioblastoma, the most aggressive type of brain cancer.
A new study provides the possibility to evaluate the capacity of telomerase-positive human urine-derived stem cells to become a wide variety of other cell types.
